Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Cancer Research
|
October 7, 2022
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Gwo Yaw Ho, Elizabeth L Kyran, Justin Bedo, et al.
Molecular Cancer
|
August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
Ksenija Nesic, John J Krais, Yifan Wang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
May 4, 2023
Targeting homologous recombination deficiency in uterine leiomyosarcoma
Genevieve Dall, Cassandra J Vandenberg, Ksenija Nesic, et al.
Nature Communications
|
November 5, 2025
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
Chee Khoon Lee, Apriliana E R Kartikasari, Nirashaa T Bound, et al.
Cancer Discovery
|
June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
NAR Cancer
|
July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
Rachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Cell Death & Disease
|
March 13, 2021
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors
Christoph Grohmann, Francesca Walker, Mark Devlin, et al.
Gynecologic Oncology
|
January 7, 2020
Therapeutic options for mucinous ovarian carcinoma
Kylie L Gorringe, Dane Cheasley, Matthew J Wakefield, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 30, 2020
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
Eun Young Kang, Dane Cheasley, Cecile LePage, et al.
Nature
|
May 15, 2007
Genome of the marsupial Monodelphis domestica reveals innovation in non-coding sequences
Tarjei S Mikkelsen, Matthew J Wakefield, Bronwen Aken, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Cancer Research
|
October 7, 2022
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Gwo Yaw Ho, Elizabeth L Kyran, Justin Bedo, et al.
Molecular Cancer
|
August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
Ksenija Nesic, John J Krais, Yifan Wang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
May 4, 2023
Targeting homologous recombination deficiency in uterine leiomyosarcoma
Genevieve Dall, Cassandra J Vandenberg, Ksenija Nesic, et al.
Nature Communications
|
November 5, 2025
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
Chee Khoon Lee, Apriliana E R Kartikasari, Nirashaa T Bound, et al.
Cancer Discovery
|
June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
NAR Cancer
|
July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
Rachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Cell Death & Disease
|
March 13, 2021
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors
Christoph Grohmann, Francesca Walker, Mark Devlin, et al.
Gynecologic Oncology
|
January 7, 2020
Therapeutic options for mucinous ovarian carcinoma
Kylie L Gorringe, Dane Cheasley, Matthew J Wakefield, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 30, 2020
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
Eun Young Kang, Dane Cheasley, Cecile LePage, et al.
Nature
|
May 15, 2007
Genome of the marsupial Monodelphis domestica reveals innovation in non-coding sequences
Tarjei S Mikkelsen, Matthew J Wakefield, Bronwen Aken, et al.
Page
of 7